HER2 Dual Blockade in Early Stage HER2+ Breast Cancer
Dr. VK Gadi and an expert panel of oncologists share insight on the optimal use of HER2 dual-blockade strategies in patients with early-stage HER2+ breast cancer.
The University of Illinois Cancer Center serves as a Strategic Alliance Partner with OncLive. View our complete video library.